Cellular physiology and biochemistry, 2017-01, Vol.42 (4), p.1366-1376
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells
- Ist Teil von
- Cellular physiology and biochemistry, 2017-01, Vol.42 (4), p.1366-1376
- Ort / Verlag
- Basel, Switzerland: S. Karger AG
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Abstract Background/Aims: Istaroxime is a validated inotropic Na+/K+ ATPase inhibitor currently in development for the treatment of various cardiac conditions. Recent findings established that this steroidal drug exhibits potent apoptotic responses in prostate tumors in vitro and in vivo, by affecting key signaling orchestrating proliferation and apoptosis, such as c-Myc and caspase 3, Rho GTPases and actin cytoskeleton dynamics. In the present study we examined whether istaroxime is affecting cell motility and analyzed the underlying mechanism in prostate tumor cells. Methods: Migration was assessed by transwell and wound healing assays, Orai1 and Stim1 abundance by RT-PCR and confocal immunofluorescence microscopy, Fura-2 fluorescence was utilized to determine intracellular Ca2+ and Western blotting for FAK/pFAK measurements. Results: We observed strong inhibition of cell migration in istaroxime treated DU-145 prostate cancer cells. Istaroxime further decreased Orai1 and Stim1 transcript levels and downregulated Orai1 protein expression. Moreover, SOCE was significantly decreased upon istaroxime treatment. Furthermore, istaroxime strikingly diminished phosphorylated FAK levels. Interestingly, the efficacy of istaroxime on the inhibition of DU-145 cell migration was further enhanced by blocking Orai1 with 2-APB and FAK with the specific inhibitor PF-00562271. These results provide strong evidence that istaroxime prevents cell migration and motility of DU-145 prostate tumor cells, an effect at least partially attributed to Orai1 downregulation and FAK de-activation. Conclusion: Collectively our results indicate that this enzyme inhibitor, besides its pro-apoptotic action, affects motility of cancer cells, supporting its potential role as a strong candidate for further clinical cancer drug development.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1015-8987eISSN: 1421-9778DOI: 10.1159/000479200Titel-ID: cdi_doaj_primary_oai_doaj_org_article_22e8bd753f2b4fe7958893ca236fe546
- Format
- –
- Schlagworte
- Antibodies, Calcium - metabolism, Calcium Channels - genetics, Calcium Channels - metabolism, Cell culture, Cell growth, Cell Line, Tumor, Cell Movement - drug effects, DU-145 prostate cancer cells, Enzymes, Epithelial Cells - drug effects, Epithelial Cells - metabolism, Epithelial Cells - pathology, Etiocholanolone - analogs & derivatives, Etiocholanolone - pharmacology, Experiments, FAK, Fluorescent Dyes - chemistry, Focal Adhesion Kinase 1 - antagonists & inhibitors, Focal Adhesion Kinase 1 - genetics, Focal Adhesion Kinase 1 - metabolism, Fura-2 - chemistry, Gene Expression Regulation, Neoplastic, Humans, Istaroxime, Lasers, Male, Membranes, Microscopy, Migration, Motility, Neoplasm Proteins - antagonists & inhibitors, Neoplasm Proteins - genetics, Neoplasm Proteins - metabolism, Orai1, ORAI1 Protein - antagonists & inhibitors, ORAI1 Protein - genetics, ORAI1 Protein - metabolism, Original Paper, Phosphorylation, Phosphorylation - drug effects, Prostate - drug effects, Prostate - metabolism, Prostate - pathology, Prostate cancer, Protein Kinase Inhibitors - pharmacology, Proteins, Pyrimidines - pharmacology, Signal Transduction, SOCE, Sodium Channel Blockers - pharmacology, Software, Stromal Interaction Molecule 1 - antagonists & inhibitors, Stromal Interaction Molecule 1 - genetics, Stromal Interaction Molecule 1 - metabolism, Sulfonamides - pharmacology, Tumors